1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol;1-(propan-2-ylamino)-3-(2-prop-2-enylphenoxy)propan-2-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol;1-(propan-2-ylamino)-3-(2-prop-2-enylphenoxy)propan-2-ol
• 化学式: C29H43N3O4
• 分子量: 497.7
• InChiKey: PFEHEECGSYOUPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.06
• 重原子数：
  36
• 可旋转键数：
  14
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  98.8
• 氢给体数：
  5
• 氢受体数：
  6

文献信息

• DEUTERATED AMINOGLYCIDAL COMPOUNDS
  申请人：Gant Thomas G.

  公开号：US20090182057A1

  公开（公告）日：2009-07-16

  Provided herein are substituted aminoglycidyl compounds of Formula (1), processes of preparation, and pharmaceutical compositions thereof and methods of their use for treating, preventing, or ameliorating one or more symptoms of a social anxiety disorder, an anxiety disorder, hyperthyroidism, tremor, glaucoma, hypertension, coronary artery bypass graft, chronic stable angina, atrial arrhythmia, migraine, bleeding esophageal varices, hypertrophic subaortic stenosis, heart failure, post-myocardial infarction, decreased left ventricular function after recent myocardial infarction, and/or any disorder ameliorated by beta adrenergic receptor modulators.

  本文提供了一种式子为（1）的取代氨基环氧丙烷化合物，其制备方法，以及其制药组合物和用于治疗、预防或缓解社交焦虑症、焦虑症、甲状腺功能亢进、震颤、青光眼、高血压、冠状动脉搭桥手术、慢性稳定型心绞痛、心房心动过速、偏头痛、食管静脉曲张出血、肥厚性主动脉瓣下狭窄、心力衰竭、心肌梗死后、近期心肌梗死后左心室功能下降和/或任何通过β肾上腺素能受体调节剂缓解的疾病的治疗方法。
• [EN] NOVEL PHARMACOGENE SINGLE NUCLEOTIDE POLYMORPHISMS AND METHODS OF DETECTING SAME<br/>[FR] NOUVEAUX POLYMORPHISMES SIMPLE NUCLÉOTIDE PHARMACOGÈNES ET PROCÉDÉS DE DÉTECTION DE CEUX-CI
  申请人：ASSURERX HEALTH INC

  公开号：WO2013181256A2

  公开（公告）日：2013-12-05

  The present invention provides pharmacogene polymorphisms and their use in predicting therapeutic effectiveness. The present invention also provides methods comprising targeted analysis of selected pharmacogenes in thousands of compiled whole human genome sequences for identifying polymorphic sequences associated with drug response are described, The methods also provide confirmation and validation of these pharmacogene polymorphisms, based on concordance between different sequencing technologies, and statistical error-checking. Imputation of the deleterious consequences of novel variants is predicted by bioinformatics analysis.